The Nutshell

Daily News Roundup

Most Recent

Stem cell strength in numbers

By | July 30, 2008

Embryonic stem cells are a tricky business, as evidenced by Advanced Cell Technology's linkurl:recently announced; financial woes. The technology is too nascent for guaranteed returns, but potential payoffs could be huge. Increasingly, biotechs are looking to navigate the uncertain funding waters by forging partnerships with pharmaceutical companies. Some biotechs working on embryonic stem cells have been able to get start up money from the state


A micro-microscope

By | July 28, 2008

Engineers at the California Institute of Technology have designed a dime-sized lensless microscope able to capture high-resolution images of cells and pathogens. The low-cost, portable technology could be an ideal tool for use in developing countries, according to the linkurl:paper,; published online today (July 28) in the Proceedings of the National Academy of Sciences. Despite the trend towards miniaturization evident in the popularity of l


Researchers may abandon stem cell lines

By | July 28, 2008

Leading US research institutions may stop studying several federally-fundable linkurl:embryonic stem cell; lines due to potential ethical problems surrounding the creation of the lines. As linkurl:reported; by __The Chronicle of Higher Education__ today (July 28), Stanford and Johns Hopkins Universities, and the linkurl:California Institute for Regenerative Medicine;


Tackling peer review bias

By | July 28, 2008

New statistical analyses of the National Institutes of Health's peer review process suggest that the current system may be missing the mark on funding the right proposals. Reviews of as many as 25% of all proposals are biased, according to a study led by linkurl:Valen Johnson,; from MD Anderson Cancer Center to be published tomorrow (July 29) in Proceedings of the National Academy of Sciences. Johnson collected about 14,000 reviewers' scoring data


Duke investigating misconduct?

By | July 25, 2008

The Duke University Medical Center has agreed to conduct an inquiry into allegations of misconduct against Duke protein biochemist linkurl:Homme Hellinga,; according to a linkurl:letter; Hellinga wrote to Nature, which was published in the journal this week. Hellinga retracted two papers earlier this year that claimed to have redesigned ribose-binding protein (RBP) to catalyze trio

1 Comment

Fauci lays out HIV research plan

By | July 24, 2008

A week after suspending a major HIV vaccine trial set to commence soon, linkurl:Anthony Fauci,; head of the National Institute of Allergies and Infectious Diseases (NIAID), has laid out a plan for reshuffling priorities in HIV/AIDS vaccine development in an article appearing in Science tomorrow (July 25), coauthored by a slew of HIV vaccine researchers. "The general trend will be funding a bit more fundamental discovery research," Fauci said,


Founder of medical genetics dies

By | July 24, 2008

Victor McKusick, who founded the field of medical genetics at Johns Hopkins University, died on Tuesday, July 22, at his home outside Baltimore. He was 86 years old. "Victor's vision is reflected in his early recognition of the inherent value to medicine of mapping the human genome," said Aravinda Chakravarti, director of the McKusick-Nathans Institute in a 2002 linkurl:statement.; "His contributions to the practice of genetics in medicin


Rethinking aging

By | July 24, 2008

Aging may not be caused by the accumulation of cellular damage, as a linkurl:prominent theory; suggests. Instead, the process may result from the deterioration of crucial developmental pathways, according to a study published tomorrow in Cell. "What we found is, I think, a different way to think about aging," linkurl:Stuart Kim; of Stanford University, main author of the study, told The Scientist. Kim and his coll


Biotech bailing on stem cells?

By | July 23, 2008

The announcement last week of Advanced Cell Technology's imminent closure is evidence that embryonic stem cell technology may be linkurl:too nascent; for fruitful biotech innovation, according to some industry analysts. For the past 10 years Advanced Cell Technology (ACT) has been a spotlight company for linkurl:endeavors; in embryonic stem cell research and cloning. But in a Securities and Exchange


Another biotech buy for Roche

By | July 22, 2008

After making a $43.7 billion offer linkurl:yesterday; (July 21) to buy the 44% of Genentech stock it didn't already own, the Swiss pharmaceutical company announced another biotech purchase today. Roche will acquire linkurl:Mirus Bio Corporation; for $125 million. Roche's half-year financial linkurl:results,; released on Monday but eclipsed by the Genentech offer,



Popular Now

  1. Most Earth-like Planet Found
  2. When Does a Smart Mouse Become Human?
  3. AAAAA Is for Arrested Translation
  4. Antibiotic Resistance Can Boost Bacterial Fitness
The Scientist